Nicardipine may impair glucose metabolism in hypertensive diabetic patients.
The respective effects of 6 month's administration of beta-blockers (atenolol, metoprolol, carteolol and arotinolol), calcium-channel blockers (nicardipine, diltiazem) and angiotensin converting enzyme inhibitor (enalapril) on hemoglobin A1c (HbA1c) levels were evaluated in hypertensive patients with non-insulin-dependent diabetes mellitus (NIDDM), using a retrospective method. NIDDM patients with stable HbA1c and body weight were selected for this study. The following results were obtained. (1) The administration of nicardipine or beta-blockers significantly elevated HbA1c levels. (2) The administration of diltiazem or enalapril did not have any influence on HbA1c levels. These findings suggest that not only beta-blocker but nicardipine (dihydropyridine type calcium-channel blocker) may cause deterioration in glucose metabolism in NIDDM patients.
Sasaki
H
H
First Department of Medicine, Wakayama University of Medical Science, Japan.
Naka
K
K
Kishi
Y
Y
Ohoshi
T
T
Hagihara
T
T
Matsuo
H
H
Sowa
R
R
Matsumoto
G
G
Sanke
T
T
Nanjo
K
K
D000328:Adult; D000368:Aged; D001262:Atenolol / Q000009:adverse effects; D002354:Carteolol / Q000009:adverse effects; D003924:Diabetes Mellitus, Type 2 / Q000150:complications* / Q000378:metabolism; D004110:Diltiazem / Q000009:adverse effects; D004656:Enalapril / Q000009:adverse effects; D005260:Female; D005947:Glucose / Q000378:metabolism*; D006442:Glycated Hemoglobin / Q000032:analysis / Q000187:drug effects; D006801:Humans; D006973:Hypertension / Q000150:complications* / Q000188:drug therapy; D008297:Male; D008790:Metoprolol / Q000009:adverse effects; D008875:Middle Aged; D009529:Nicardipine / Q000009:adverse effects* / Q000627:therapeutic use; D011412:Propanolamines / Q000009:adverse effects
D001262:Atenolol; D002354:Carteolol; D004110:Diltiazem; D004656:Enalapril; D005947:Glucose; D006442:Glycated Hemoglobin; D008790:Metoprolol; D009529:Nicardipine; D011412:Propanolamines; C024523:arotinolol